NASDAQ$OMGAQ
Omega Therapeutics Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Omega Therapeutics reported second quarter 2022 financial results and highlighted recent company progress.
Omega Therapeutics reported a net loss of $25.9 million for the second quarter of 2022. The company's cash, cash equivalents and marketable securities totaled $173.7 million as of June 30, 2022. They also received FDA clearance for OTX-2002 IND application.
- Received FDA Clearance of IND Application for OTX-2002, the First Ever Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma
- Launched Phase 1/2 Clinical Trial Under the MYCHELANGELOTM Clinical Program in Patients Expected in 2H’22
- Data from Preclinical Studies Show Promising Anti-Tumor Activity and Loss of Cancer Cell Viability Achieved Through Pre-Transcriptional Downregulation of MYC Gene Expression
- $173.7 Million in Cash, Cash Equivalents and Marketable Securities at End of Second Quarter
Headline financials
Revenue & EPS history
Omega Therapeutics · Revenue · Quarterly
$476K
Forward guidance
This press release contains forward-looking statements regarding the timing and design of our Phase 1/2 MYCHELANGELOTM clinical trial; the potential of the OMEGA platform; expectations surrounding the potential of our product candidates, including our lead OEC candidate OTX-2002; and expectations regarding our pipeline.
Tailwinds
- timing and design of our Phase 1/2 MYCHELANGELOTM clinical trial
- the potential of the OMEGA platform
- expectations surrounding the potential of our product candidates, including our lead OEC candidate OTX-2002
- expectations regarding our pipeline
- initiation of preclinical studies and advancement of multiple preclinical development programs in oncology, immunology, regenerative medicine, and select monogenic diseases
Headwinds
- the novel technology on which our product candidates are based makes it difficult to predict the time and cost of preclinical and clinical development and subsequently obtaining regulatory approval, if at all
- the substantial development and regulatory risks associated with epigenomic controller machines due to the novel and unprecedented nature of this new category of medicines
- our limited operating history
- the incurrence of significant losses and the fact that we expect to continue to incur significant additional losses for the foreseeable future
- our need for substantial additional financing
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 9 quarterly earnings reports
-5.1%
Avg return
Earnings day
-8.9%
Avg return
5 days after
-12.9%
Avg return
30 days after
47%
7 / 15 earnings
Positive
+14.2%
Q1 2023
Best reaction
-47.5%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -47.5% | -25.0% | -44.8% | |
| Q3 2024 | -22.6% | -30.7% | -9.2% | |
| Q2 2024 | -0.6% | +0.0% | -11.3% | |
| Q1 2024 | -16.7% | -16.1% | -17.3% | |
| Q4 2023 | -9.9% | -15.3% | -36.6% | |
| Q3 2023 | -3.4% | +5.1% | +28.7% | |
| Q2 2023 | +2.4% | -14.2% | -23.8% | |
| Q1 2023 | +14.2% | +9.1% | +4.4% | |
| Q4 2022 | +5.6% | +7.0% | -6.7% | |
| Q3 2022 | -3.8% | — | — | |
| Q2 2022 | +9.3% | — | — | |
| Q1 2022 | +0.3% | — | — | |
| Q4 2021 | -6.4% | — | — | |
| Q3 2021 | +1.5% | — | — | |
| Q2 2021 | +0.9% | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro